6. Vaccine according to any one of claims 1 to 5, characterized in that the carrier is a protein carrier.

7. Vaccine according to claim 6, characterized in that the protein carrier is selected from the group consisting of keyhole limpet haemocyanin (KLH), tetanus toxoid (TT) or diphtheria toxin (DT).

8. Vaccine according to any one of claims 1 to 7, characterized in that the compound is formulated with an adjuvant, preferably adsorbed to alum.

~~9. Vaccine according to any one of claims 1 to 8 for use in the treatment of a complement-mediated disorder.~~

~~10. Vaccine according to claim 9, characterized in that the complement-mediated disorder is an inflammatory disease, preferably a chronic inflammatory disease.~~

~~11. Vaccine according to claim 10, characterized in that the inflammatory disease is selected from the group consisting of age-related macular degeneration (AMD), a neurodegenerative disorder, preferably Alzheimer's disease, Parkinson's disease or Huntington's disease, asthma, atherosclerosis, vasculitis, dermatitis, preferably psoriasis and urticaria, hemolytic uremic syndrome, rheumatoid arthritis, Guillain-Barre syndrome, multiple sclerosis, antiphospholipid syndrome, hemolytic uremic syndrome, and systemic lupus erythematosus (SLE).~~

~~12. Vaccine according to claim 9, characterized in that the complement-mediated disorder is selected from the group consisting of ischemia/reperfusion injury, acute lung injury, acute respiratory distress syndrome, sepsis, cancer, pregnancy complications such as preeclampsia, recurrent spontaneous abortions, intra-uterine growth retardation and antiphospholipid syndrome, and hemodialysis-associated thrombosis.~~